SERA

Sera Prognostics Inc

SERA, USA

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

https://www.sera.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SERA
stock
SERA

Lindgardt, Sera Prognostics CEO, sells $13k in shares By Investing.com Investing.com Nigeria

Read more →
SERA
stock
SERA

Sera Prognostics general counsel sells $2952 in stock By Investing.com Investing.com Australia

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$2.75

Analyst Picks

Strong Buy

2

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Medium

2.12

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-9.51 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-7.23 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-41,181.25 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.32

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 56.99% of the total shares of Sera Prognostics Inc

1.

Baker Bros Advisors LP

(14.4453%)

since

2025/06/30

2.

Whetstone Capital Advisors, LLC

(9.5433%)

since

2025/06/30

3.

Aberdeen Group PLC

(5.852%)

since

2025/06/30

4.

Vivo Capital, LLC

(4.3362%)

since

2025/06/30

5.

Vanguard Group Inc

(3.056%)

since

2025/06/30

6.

abrdn Healthcare Investors

(3.0102%)

since

2025/08/31

7.

abrdn Healthcare Opportunities

(2.9793%)

since

2025/07/31

8.

Vanguard Total Stock Mkt Idx Inv

(1.9557%)

since

2025/07/31

9.

Awm Investment Company Inc

(1.789%)

since

2025/06/30

10.

Citadel Advisors Llc

(1.6526%)

since

2025/06/30

11.

CapTrust Financial Advisors

(1.5824%)

since

2025/06/30

12.

Geode Capital Management, LLC

(0.7945%)

since

2025/06/30

13.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7327%)

since

2025/07/31

14.

SMH Capital Inc.

(0.6926%)

since

2025/06/30

15.

Millennium Management LLC

(0.4849%)

since

2025/06/30

16.

Fidelity Extended Market Index

(0.3867%)

since

2025/07/31

17.

BlackRock Inc

(0.3817%)

since

2025/06/30

18.

Perkins Capital Management Inc

(0.3442%)

since

2025/06/30

19.

State Street Corp

(0.3195%)

since

2025/06/30

20.

CI Private Wealth LLC

(0.2627%)

since

2025/06/30

21.

Wealth Enhancement Advisory Services, LLC

(0.2605%)

since

2025/06/30

22.

Northern Trust Corp

(0.2408%)

since

2025/06/30

23.

Morgan Stanley - Brokerage Accounts

(0.2401%)

since

2025/06/30

24.

Squarepoint Ops LLC

(0.2244%)

since

2025/06/30

25.

CLIFTONLARSONALLEN WEALTH ADVISORS, LLC

(0.2072%)

since

2025/06/30

26.

iShares Micro-Cap ETF

(0.1639%)

since

2025/08/31

27.

Fidelity Total Market Index

(0.1342%)

since

2025/07/31

28.

Bridgeway Ultra-Small Company Market

(0.108%)

since

2025/06/30

29.

Extended Equity Market Fund K

(0.1077%)

since

2025/06/30

30.

Fidelity Series Total Market Index

(0.096%)

since

2025/07/31

31.

Spartan Extended Market Index Pool F

(0.0923%)

since

2025/07/31

32.

Goldman Sachs Absolute Ret Trckr Instl

(0.0738%)

since

2025/06/30

33.

NT Ext Equity Mkt Idx Fd - L

(0.0735%)

since

2025/06/30

34.

Northern Trust Extended Eq Market Idx

(0.0735%)

since

2025/06/30

35.

NT Ext Equity Mkt Idx Fd - NL

(0.0638%)

since

2025/06/30

36.

Fidelity Nasdaq Composite Index

(0.0609%)

since

2025/07/31

37.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0495%)

since

2025/06/30

38.

Spartan Total Market Index Pool G

(0.0471%)

since

2025/07/31

39.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0354%)

since

2024/12/31

40.

Schwab Total Stock Market Index

(0.0315%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.185

Latest Release

Date

2025-09-30

EPS Actual

-0.16

EPS Estimate

-0.23

EPS Difference

0.07

Surprise Percent

30.4348%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.